Strategic Planning Facilitator

I've written the full planning package as one document: situation assessment, options for all four questions, the four priorities, a "not doing" list, decision criteria, governance, the two-day agenda and a draft board story.

The draft plan in brief. Everything below is marked PROPOSED. Ruth and the leadership team make the calls.

The main finding: driver turnover (71%, up from 58% in 2024) is the constraint on everything else. The warehouse, pharma and LTL growth all need drivers who stay.

The four questions are really one money question. The $22M warehouse takes about 73% of the undrawn revolver. Funded entirely with debt, it would take net debt from about 3.1x EBITDA to about 4.5x (illustrative). Driver pay, pharma certification and any emissions spending draw on the same money.

• The four proposed priorities:
  1. Driver retention. Owner not provided.
  2. Defending the core accounts as shippers cut carriers. Owner not provided.
  3. Raising warehouse prices and improving the customer mix now, with the $22M build decided at a go/no-go review in Q3 2027. Owner: Marta.
  4. A small pharma entry at one certified site. Owner: Anil.

Gregor's debt paydown is treated as a leverage ceiling that every priority must respect, rather than as a fifth priority. It honours his position without taking a slot.

Marta vs. Gregor on the warehouse: the go/no-go review turns their disagreement into criteria Ruth can rule on: anchor customers committed, turnover falling, leverage within the ceiling, and whether the site must be pharma-ready.

Not doing: two decisions are already made (exit Florida produce; no sale before 2029). Six are proposed, including no brokerage arm, no price-matching brokers on spot lanes, and no $22M commitment before the go/no-go review.

The agenda: 18–19 Feb 2027 is a Thursday and Friday. Every session ends with a named decision. If the team can't agree, Ruth decides before the next session, because the team is split and she hasn't taken a side. Pre-reads are due 4 Feb.

Gaps you need to fill. Every figure in the document comes from your notes or is simple arithmetic on them, with the working shown. Anything missing is marked NOT PROVIDED, including:

• owners for brokerage, driver retention and the core accounts;
• what the $22M covers, how long the build takes, and the payback;
• which pharma certification is needed, and its cost and timeline;
• Gregor's leverage ceiling and covenants;
• headcount and driver counts;
• emissions exposure;
• margin by segment;
• the PE investor's expectations;
• the board meeting date.

All of these are in the Open Questions section, with suggested owners.

Two time-sensitive points:

• The Florida exit (end of Q1 2027) can't wait for the offsite to tell customers, so the roadmap starts that communication now.
• The driver turnover diagnosis has no owner yet, and Day 1 depends on it. Name someone this month.

The board story is a draft. Gregor and counsel should review it before it goes to the board or the PE investor. All decisions are still open until the offsite.

Deliverable

I can also convert it to Word or a board slide deck.

---

The file it wrote: halvorsen-strategic-plan-2027-2028.md

Halvorsen Freight Systems — Strategic Planning Package

Horizon: January 2027 – June 2028 (18 months)
Leadership offsite: Thursday 18 – Friday 19 February 2027
Feeds: Board strategy session, March 2027 (exact date NOT PROVIDED)
Status: DRAFT for leadership review. Claude structured this from the CEO-office notes. Every strategic choice in it is marked

DECIDED (decided before this draft, with who decided) or

PROPOSED — leadership decision required. Nothing here is decided until the leadership team decides it at the offsite.

Labels used in this document

• DECIDED: already settled. The source is named.
• PROPOSED: a recommended draft position. Leadership must confirm, change or reject it.
• ASSUMPTION: an inference that is not in the input notes. Confirm or correct it before the offsite.
• NOT PROVIDED: a figure or fact the notes don't contain. It must not be filled in by guesswork.
• Derived: arithmetic on the input figures only, with the working shown.

Fit check. A full strategic plan suits Halvorsen. The company is profitable (8.4% EBITDA margin), its last plan ("LTL density first") mostly worked, and it is not in crisis. It faces four real, competing capital and focus choices, and leadership is split. That is the situation this framework is built for.

---

Situation Assessment

External factors

Internal view

Capabilities and assets

• An asset-based network: 640 tractors and three cold-storage warehouses (Columbus, Indianapolis, Louisville).
• An integrated offer across three segments: refrigerated LTL ($94M, 50.5% of FY2026 forecast), dedicated contract carriage ($61M, 32.8%) and warehousing ($31M, 16.7%). The segment shares are derived and sum to $186M.
• The 2024–2026 "LTL density first" plan mostly worked. Halvorsen has executed a focused strategy before.
• It survives consolidation RFPs: it kept both top-10 customers that halved their carrier lists.

Resource position

• FY2026 forecast revenue is $186M, up 9.0% from $170.6M in FY2025.
• EBITDA is about $15.6M (8.4% margin).
• Net debt is $48M, about 3.1x EBITDA (derived: 48 ÷ 15.6). The $30M revolver is undrawn.
• Free cash flow, capex commitments, interest cost, covenants and leverage targets are all NOT PROVIDED. Without them, debt paydown can't be projected.
• 1,450 employees. Headcount by function and the number of drivers are NOT PROVIDED.

Constraints

Driver turnover is 71% annualized, up from 58% in 2024, a rise of 13 points. Every growth option depends on having seated, reliable drivers.

Warehouses are at 92% average occupancy. There is little room to add customers or a pharma zone without changing the customer mix or adding capacity.

Capital competes. The 4th warehouse ($22M, COO's estimate) equals about 73% of the undrawn revolver and about 1.4x annual EBITDA (derived). If it were funded entirely with debt and EBITDA stayed flat, net debt would reach about $70M, or about 4.5x EBITDA. This is illustrative only: it ignores cash generation and any EBITDA from the new site.

Ownership: the founding family holds 70% and a minority PE investor holds 30%. The company will not be sold before 2029 (DECIDED, CEO and board, September 2026). The PE investor's return and liquidity expectations are NOT PROVIDED.

Leadership is split. The CFO (Gregor Lindahl) wants debt paydown before any big bet. The COO (Marta Okafor) wants the 4th warehouse. The CEO (Ruth Halvorsen) has not taken a side.

Competitive advantages ("moats")

• Owned trucks plus owned cold storage in one region. Brokers (Brightwater, Polar Route) can't offer this. Kesterline can, and is building more of it.
• Incumbent relationships with consolidating top-10 shippers.

SWOT

Key strategic insights: what we must get right

Drivers come before every other bet. A 4th warehouse, a pharma launch and LTL density all need reliable drivers. Turnover rising from 58% to 71% erodes the main thing consolidating shippers choose a carrier for: dependable service (ASSUMPTION that service reliability drives RFP outcomes; confirm with the commercial team's RFP debriefs). Fix this first, or every other priority runs on a leaking engine.
2. Halvorsen wins where assets plus warehouses matter, and loses where price alone matters. The brokers win spot freight on price. Halvorsen's defensible ground is integrated, reliable cold capacity for shippers who are cutting their carrier lists. Kesterline is the competitor on that ground, not the brokers.
3. Capital is limited enough that the four questions are really one question. The $22M warehouse, a pharma certification, driver pay and possible reefer emissions spending all draw on the same $30M revolver and a 3.1x-leverage balance sheet. The offsite has to choose an order, not a list. The CFO and COO disagree about the order, not about whether the investments make sense. A staged go/no-go gate turns that disagreement into criteria the CEO can rule on.

---

Strategic Options

For each question below, Options A, B and C are the conservative, aggressive and alternative paths. Every recommendation is

PROPOSED — leadership decision required.

Question 1 — Build a 4th warehouse or stay at three and raise prices?

Owner: Marta Okafor (COO)

What each side must believe

• The CFO's position (A): pricing power holds against Kesterline, and lower leverage protects more value than growth adds.
• The COO's position (B): demand for cold storage in the region will absorb both Kesterline's new capacity and a Halvorsen 4th site, at a payback leadership accepts.

What would change the answer

• Signed anchor commitments for a large share of a new site would point to B.
• Renewals lost to Kesterline at the new prices would point away from both A-style pricing and B.
• An emissions rule needing major reefer spending would favor A.

PROPOSED: Option C.

Proposed gate criteria, with thresholds for leadership to set at the offsite:

1. Anchor customers committed for [X]% of the new site's capacity.
2. Driver turnover trending down for [N] consecutive months.
3. Leverage after the build within the CFO's ceiling (ceiling NOT PROVIDED).
4. A decision on whether the site must be pharma-validated (this links to Question 2).

The gate date is PROPOSED for the Q3 2027 quarterly review. It depends on build time, which is NOT PROVIDED.

Question 2 — Enter pharma and healthcare cold chain?

Owner: Anil Seshadri (VP Commercial Development)

What would change the answer

• Certification cost or timeline that pushes first revenue past mid-2028 would point to A.
• Two or more requesters giving written intent to contract once certified would point to C, accelerated.
• A pharma anchor that needs a validated new site links directly to the Question 1 gate.

PROPOSED: Option C.

Proposed go/no-go for Anil's pre-work, due before the offsite:

• Confirm which certification is required.
• Cost and timeline to certify one site.
• Size the 2026 inbound requests (volume and revenue per requester).
• Re-contact the requesters to test whether they would sign once certified.

Question 3 — Launch a brokerage arm or stay asset-based?

Owner: OWNER NOT PROVIDED

What would change the answer: if top-10 RFPs start scoring carriers on their ability to supply brokered surge capacity, revisit Option C.

PROPOSED: Option A for the horizon. Option C is held as a revisit trigger.

Question 4 — Fix driver retention through pay, scheduling technology, or both?

Owner: OWNER NOT PROVIDED

What would change the answer: if the diagnosis shows one cause dominates, go straight to the matching fix at scale.

PROPOSED: Option C, with a hard timebox. If the pilots don't show a measurable gap by the Q3 2027 review, move to Option B.

---

Where to Play / How to Win

Source of advantage (PROPOSED, in one sentence): Halvorsen is the Midwest cold-chain carrier that consolidating shippers can rely on, because it owns the trucks, the drivers and the cold storage, and brokers can't promise that.

---

Trade-offs

---

What We're Not Doing

No priority below contradicts this list. Check: Priority 3 keeps the warehouse decision gated, and Priority 4 is limited to a beachhead.

---

Strategic Priorities

There are four priorities, matching the user's cap. All are PROPOSED. Targets in [brackets] are for leadership to set. They are not in the inputs.

Priority 1 — Keep the trucks seated (driver retention)

• Rationale: Turnover is 71% and rising, up from 58% in 2024. Every other priority depends on fixing it.

Success metrics: Annualized turnover from 71% to [target]. A reference point is the 2024 level of 58%, which is not a target until leadership sets one. Also first-90-day attrition [NOT PROVIDED baseline] and seated-truck ratio [NOT PROVIDED baseline].

• Resources: Pay and technology budget NOT PROVIDED. Analytics capacity NOT PROVIDED.
• Owner: OWNER NOT PROVIDED. A head of People or driver recruiting is not named in the inputs.
• Milestones:
  • Q1 2027: diagnosis of causes by segment and terminal, with a targeted action in the worst segment.
  • Q2 2027: pay and scheduling pilots running.
  • Q3 2027: pilot readout and scale decision. Option B fallback if no clear result.
  • Q4 2027 to Q2 2028: scaled fix, with turnover trending to target.
• Dependencies: Exit and tenure data. CFO sign-off on the pay budget.
• Risks: Turnover keeps rising during the pilots. Competitors match pay.

Priority 2 — Win the consolidation (defend and densify the core)

Rationale: Shippers are halving their carrier lists. Continuing LTL density and protecting the top accounts protects the base. The Florida exit is part of the same density logic.

Success metrics: Win rate in top-account RFPs [target]. Revenue retained in top-10 accounts [NOT PROVIDED baseline]. LTL density measure [metric used in the 2024–2026 plan; NOT PROVIDED]. Florida exit complete by 31 March 2027.

• Resources: Commercial team effort. Budget NOT PROVIDED.

Owner: OWNER NOT PROVIDED. The commercial lead for core accounts is not named. Anil Seshadri is named only for pharma.

• Milestones:
  • Q1 2027: Florida exit complete. An RFP calendar mapped for the top 10.
  • Q2 to Q4 2027: account plans for each top-10 shipper.
  • 2028: a debrief after every RFP fed into the quarterly review.
• Dependencies: Service reliability, which depends on Priority 1.
• Risks: Losing a top-10 RFP. Kesterline bundling warehousing with trucking.

Priority 3 — Earn the 4th warehouse (price and mix now, gate the build)

Rationale: At 92% occupancy, the existing space is underpriced or misallocated. The $22M build should be earned through evidence, not assumed. This is the PROPOSED synthesis of the CFO's and COO's positions, and the CEO decides.

Success metrics: Warehousing revenue per occupied position [NOT PROVIDED baseline]. Renewal price realization [target]. Gate criteria met or not met at the Q3 2027 review.

• Resources: $22M capex only if the gate passes (COO's estimate). Pre-development cost NOT PROVIDED.
• Owner: Marta Okafor (COO)
• Milestones:
  • Q1 2027: pricing and mix plan, plus a business case with site options.
  • Q2 2027: anchor-customer conversations, and Kesterline pricing and occupancy evidence.
  • Q3 2027: go/no-go gate.
  • Q4 2027 to Q2 2028: either start the build (if go) or continue optimizing the three sites (if no-go).

Dependencies: The CFO's leverage ceiling. The pharma decision (whether a site must be validated). Driver capacity.

• Risks: Customers move to Kesterline after price rises. The gate slips.

Priority 4 — Certified healthcare cold-chain beachhead

• Rationale: About a dozen requesters in 2026 asked for this, so the demand is already evidenced.

Success metrics: Certification achieved at one site by [date]. Requesters converted [target number]. Healthcare revenue run-rate by June 2028 [target].

• Resources: Certification, validated equipment and a compliance lead. All costs NOT PROVIDED.
• Owner: Anil Seshadri (VP Commercial Development)
• Milestones:
  • Pre-offsite: certification scope, cost and demand sizing.
  • Q2 2027: site chosen and certification started.
  • Timing of certification NOT PROVIDED. Target: first certified shipments within the horizon.
  • Q2 2028: decide whether to expand.
• Dependencies: Warehouse space (Priority 3). Reliable drivers (Priority 1).
• Risks: Certification takes longer than the horizon. Requesters have moved to other carriers by then.

Balance-sheet guardrail (not a fifth priority): The CFO's debt-paydown aim is treated as a constraint on all four priorities: a leverage ceiling [value NOT PROVIDED] that no decision may breach. This is PROPOSED as the way to honor the CFO's position without spending a priority slot on it.

---

Resource Allocation

PROPOSED funding order, which leadership must confirm:

1. Driver retention.
2. The pharma beachhead.
3. Debt paydown up to the leverage ceiling.
4. The 4th warehouse, only after the gate.

Emissions spending is held as a contingency claim on the revolver until the rule's timing is known. The CFO should bring a sources-and-uses view to the offsite. Without it, Session 2.4 can't close.

---

Decision Criteria

PROPOSED weighted screen for new opportunities (lanes, large customer requests, capex, partnerships):

Thresholds (PROPOSED): below 60, decline. From 60 to 75, pursue only if it fits within the existing budget. Above 75, bring it to the quarterly review for funding.

Automatic "no":

• It would breach the leverage ceiling.
• It is spot freight priced to match a broker.
• It is outside the Midwest.
• It needs drivers that can't be staffed at current turnover.
• It implies a sale before 2029.
• It needs unplanned capex above [$ threshold, NOT PROVIDED] outside the quarterly review.

---

Alignment Cascade

Decision rights (PROPOSED)

---

Governance and Update Triggers

Quarterly strategy review (PROPOSED; half-day each):

• Q2 2027 (May): first progress review.
• Q3 2027 (August): warehouse gate and driver-pilot readout. This is the deep review.
• Q4 2027 (November): FY2028 budget alignment.
• Q1 2028 (February): annual refresh.
• Q2 2028 (May): close-out review and next-plan kickoff.

Each review covers

1. External changes (competitors, regulation, RFPs).
2. Priority metrics.
3. Gate decisions.
4. Reallocation.

Update triggers. Any one of these forces an off-cycle review:

• The state emissions rule is finalized or gets a compliance date.
• A top-10 shipper launches an RFP, or a top-10 account is lost.
• Driver turnover stays above [X]% for 2 consecutive months.
• Kesterline adds capacity or Brightwater or Polar Route enters Halvorsen's contract accounts.
• Leverage approaches the ceiling.
• A pharma anchor customer signs, or certification slips more than one quarter.
• Warehouse occupancy falls below [X]%.
• Regional demand growth departs materially from the 4–5% estimate.
• The PE investor raises a liquidity or governance request.

---

Offsite Agenda

Thursday 18 – Friday 19 February 2027

Participants: Ruth Halvorsen (CEO, decision-maker of last resort), Gregor Lindahl (CFO), Marta Okafor (COO), Anil Seshadri (VP Commercial Development). Other attendees (People, LTL and dedicated leaders) are NOT PROVIDED. Facilitator NOT PROVIDED.

Ground rule: Every session ends with a written decision. If the team can't agree within the session's time, the CEO decides before the next session starts. Leadership is split, and the CEO has not taken a side, so this rule is what stops the offsite ending in "good discussion".

Pre-read (circulate by Thursday 4 February 2027):

• This package.
• COO: the 4th-warehouse business case (cost, build time, payback, anchor demand) and a Kesterline capacity scan.
• VP Commercial Development: certification scope, cost and timeline, plus sizing of the 2026 requesters.
• CFO: leverage ceiling, covenants, a free-cash-flow outlook and sources and uses.
• Owner TBD: driver turnover by cause, segment and terminal.
• Owner TBD: emissions-rule exposure (number of reefer units and cost ranges).
• Commercial: debriefs from the two 2026 carrier-cut RFPs.

Day 1 — Thursday 18 February: Context and the three capital questions

Day 2 — Friday 19 February: Choices, priorities, the "not doing" list, the board story

Draft board story (to be finished in Session 2.6; CFO and counsel to review before it goes to the board or the PE investor)

"Our 2024–26 density plan worked: revenue grew 9% to $186M while the market grew an estimated 4–5%. Shippers are now halving their carrier lists. We kept both customers who did so in 2026, and the next 18 months decide who survives the rest of those cuts. We will win as the Midwest cold-chain carrier shippers can rely on, because we own the trucks, the drivers and the cold storage. So we fix driver retention first. We price our full warehouses properly. We earn our way into the healthcare cold chain that is already asking for us. We commit the $22M fourth warehouse only when it meets gate criteria we are showing you today. All of this stays inside a leverage ceiling, and we are not chasing brokers on price. We are exiting Florida produce and not building a brokerage arm."

Board asks (PROPOSED):

1. Endorse the four priorities and the "Not doing" list.
2. Approve the gate criteria for the $22M warehouse decision (not the spend).
3. Note the leverage ceiling.

---

Implementation Roadmap

Communication sequence (PROPOSED):

1. Leadership team (at the offsite).
2. Board, including the PE investor's representatives if they sit on the board (board composition NOT PROVIDED). March 2027.
3. Function heads and terminal managers, with a manager toolkit.
4. Drivers, with retention changes announced only once funded. Don't preview pay changes before they are decided.
5. All employees.
6. Top-10 customers, through their account plans.
7. The 2026 pharma requesters, through Anil once certification has a date.

The Florida produce customers follow the CEO's existing exit timeline, independent of this sequence.

---

Open Questions

These gaps must be closed before or at the offsite. Owners are suggested where the inputs name one.

Owners: Who owns Question 3 (brokerage) and Question 4 (driver retention)? Who leads core-account commercial work (Priority 2)? Is there a head of People?
2.

Warehouse business case (Marta): What do the $22M cover? How long is the build? What are the expected revenue, margin and payback? Are there anchor customers? Is leasing an option? What do we know about Kesterline's occupancy and pricing?
3.

Pharma (Anil): Which certification is needed? What is the cost and timeline? What revenue would the roughly dozen 2026 requesters bring? Did any say they would come back?
4.

Balance sheet (Gregor): What leverage ceiling and covenants apply? What is the free-cash-flow outlook? What paydown target does "pay down debt first" mean?
5.

Drivers: How many drivers do we have? What does turnover look like by segment, terminal and tenure? What do exit reasons say? What does a pay change cost?
6.

Emissions: Which states? How many reefer units are exposed? What is the cost range? What is the earliest plausible compliance date?
7.

Margins: What is EBITDA by segment and by top-10 account? What is the actual margin on the Florida lanes? How big is the spot book?
8. Market: Is there any external source to check the ops team's 4–5% demand estimate?
9.

Ownership: What are the PE investor's return and liquidity expectations given no sale before 2029? Does the investor have consent rights over a $22M capex decision?
10. Logistics: When is the March 2027 board session? Who attends the offsite, and who facilitates?
11.

Targets: Leadership must set the bracketed targets (turnover, RFP win rate, warehouse gate thresholds, pharma conversion). None of them are in the inputs.